A coronavirus vaccine by a U.S. company Moderna has shown encouraging results in human safety trial.
The Massachusetts biotechnology company announced promising early results from its first human safety tests on Monday. Moderna said it plans to launch a large clinical trial in July to show whether the vaccine works.
“The company reported that in eight patients who had been followed for a month and a half, the vaccine at low and medium doses triggered blood levels of virus-fighting antibodies that were similar or greater than those found in patients who recovered. That would suggest, but doesn’t prove, that it triggers some level of immunity. The antibody-rich blood plasma donated by patients who have recovered is separately being tested to determine whether it is an effective therapy or preventive measure for covid-19,” the Washington Post reported.
The Post quoted Paul Offit, a vaccine expert at the Children’s Hospital of Philadelphia, as saying that the data looked promising and it made sense to proceed to a large trial this summer.
“The fact that the vaccine elicited neutralizing antibody amounts comparable or higher to those found in convalescent sera [plasma] is very encouraging,” said Arturo Casadevall, chair of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, who is spearheading the initiative to test plasma as a treatment, The Post reported.